Provided by Tiger Fintech (Singapore) Pte. Ltd.

Innate Pharma SA

1.87
-0.0250-1.32%
Volume:52.07K
Turnover:97.24K
Market Cap:172.34M
PE:-2.96
High:1.94
Open:1.94
Low:1.84
Close:1.90
Loading ...

Innate Pharma presents preclinical data for IPH6501 at EHA

TIPRANKS
·
13 Jun

Innate Pharma presents long-term follow-up data from TELLOMAK trial

TIPRANKS
·
23 May

Press Release: Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Dow Jones
·
13 May

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

Business Wire
·
30 Apr

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

Business Wire
·
28 Apr

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Benzinga
·
24 Apr

Innate Pharma Price Target Cut to $11.00/Share From $11.50 by HC Wainwright & Co.

Dow Jones
·
24 Apr

Innate Pharma, Sanofi Finalize Investment

MT Newswires Live
·
24 Apr

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Trump Softens Stance on Powell, Tariffs

MT Newswires Live
·
23 Apr

Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

MT Newswires Live
·
23 Apr

Innate Pharma to Propose Corporate Governance Structure Change

MT Newswires Live
·
16 Apr

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

Business Wire
·
03 Apr

European Penny Stocks To Watch In March 2025

Simply Wall St.
·
31 Mar

Innate Pharma Price Target Maintained With a $11.50/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...

GuruFocus.com
·
28 Mar

Innate Pharma FY EPS $(0.65) Down From $(0.10) YoY, Sales $22.54M Down From $66.35M YoY

Benzinga
·
27 Mar

Press Release: Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Dow Jones
·
27 Mar

Press Release: Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Dow Jones
·
20 Mar

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Business Wire
·
27 Feb

Innate Pharma Shares Rise After Breakthrough Therapy Designation for Lacutamab

Dow Jones
·
18 Feb